Opus Genetics IRD Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number at other companies

AMN HealthcareAMN

304K+29.9%

RepligenRGEN

116.8K—

The Baldwin Insurance Group, Inc.BWIN

1.7M+57.1%

Mondelez InternationalMDLZ

6.6M+14.8%

Alto Ingredients, Inc.ALTO

1.3M-17.4%

Strattec SecuritySTRT

49K-13.7%

Other financials

Income statement

See full

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

See full

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

See full

Operating cash flow-$12.7M-41.5%

Valuation

See full

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

See full

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

See full

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's share based compensation arrangement by share based payment award equity instruments other than options nonvested number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opus Genetics's share based compensation arrangement by share based payment award equity instruments other than options nonvested number?: Opus Genetics (IRD) reported share based compensation arrangement by share based payment award equity instruments other than options nonvested number of $22.9M in Q1 2026.
How has Opus Genetics's share based compensation arrangement by share based payment award equity instruments other than options nonvested number changed year-over-year?: Opus Genetics's share based compensation arrangement by share based payment award equity instruments other than options nonvested number decreased by 22.2% year-over-year, from $29.43M to $22.9M.